Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Stent Optimal Minimal Area and Stent Underexpansion Impact in 2-Stent Left Main Treatment

The upfront 2-stent strategy for left main bifurcation treatment presents a technical challenge and has been associated to higher risk of unfavorable outcomes vs provisional stenting. However, the DK-CRUSH technique has been shown to reduce the incidence of adverse events at 3 years. Even though the European Bifurcation Club stands for provisional stenting, 22% of these patients required a second stent. 

Therefore, defining left main stenting criteria is vital to improve clinical outcomes. To this end, intravascular ultrasound is used for adequate stent expansion and better clinical outcomes. 

The aim of this retrospective study was to assess optimal minimal stent area criteria for up-front left main 2-stenting and its long-term clinical outcomes.

Primary end point was major adverse cardiac events at 5 years, including all cause death, acute MI and target lesion revascularization. 

Read also: Severe Aortic Stenosis in Bicuspids: Promising Self-Expanding Valve Outcomes at 3 years.

 

The final analysis included 292 patients, mean age 64, mostly men, most presenting left main and two-vessel disease (55.8%). 6.8% presented acute coronary syndrome. Mean ejection fraction was 60% and 96% presented true angiographic bifurcation, according to Medina classification (1,1,1), (0,1,1) and (1,0,1).

Minimal stent area cutoff values for best predicting major adverse cardiovascular events at 5 years were 11.8 mm² for distal left main (area under the curve, 0.57; P = 0.15), 8.3 mm² for ostial left anterior descending artery (area under the curve, 0.62; P = 0.02) and 5.7 mm² for ostial left circumflex artery (area under the curve, 0.64; P = 0.01).

Read also: Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Using these criteria, the risk of major adverse cardiac events at 5 years was significantly associated with stent underexpansion in the ostial left anterior descending artery (HR, 3.14; CI del 95%, 1.23–8.06; P = 0.02) and the ostial left circumflex artery (HR, 2.60; CI del 95%, 1.11–6.07; P = 0.03), but not the distal left main (HR, 0.81; CI del 95%, 0.34–1.91; P = 0.63). Patients with stent underexpansion in both arteries, anterior descending and circumflex, had a significantly higher rate of major adverse cardiac events at 5 years vs. patients with no stenting or with one underexpanded stent in either ostium (P<0.01).

Conclusion

This study has shown that stent underexpasion in the anterior descending ostium and the circumflex was significantly associated with worse outcomes at long term after left main 2-stenting for left main stenosis. Minimal stent area cutoff values proposed in this study might serve was reference for left main stenting optimization. 

Original Title: Optimal Minimal Stent Area and Impact of Stent Underexpansion in Left Main Up-Front 2-Stent Strategy.

Reference: Ju Hyeon Kim et al. Circ Cardiovasc Interv. 2024;17:e013006.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

Más artículos de este Autor

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas Panamá 2026
Jornadas SOLACIspot_img

Artículos recientes

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

SOLACI Presented an Outstanding Scientific Session on Complex Coronary Lesions at EuroPCR 2026

The Latin American Society of Interventional Cardiology (SOLACI) had a prominent participation at EuroPCR 2026 through an institutional scientific session held on May 21...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...